# Jupiter Endovascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jupiter-endovascular

- Industry: Medical Devices & Equipment
- Headquarters: Menlo Park, US
- Website: www.jupiterendo.com
- Total disclosed funding: $60M
- Latest round: Series B (Oct 7, 2025)
- Investors on record: 3

## About

Based in California, US, and founded in 2024 by Alex Tilson, Jupiter Endovascular, Inc. operates as a medical technology company that focuses on providing catheter-based medicines for surgical accuracy and control. The company's flagship technology, Endoportal Control™, combines surgical precision with the simplicity of catheter interventions. Jupiter Endovascular focuses on pulmonary embolism, a serious cardiovascular condition, and they are actively advancing therapies in this area. In October 2025, Jupiter Endovascular, Inc. raised USD 40 million in series B funding led by Sonder Capital, with participation from Senvest Management and LB Investment. The company plans to use the funding from October 2025 to complete its SPIRARE II clinical trial, prepare for commercialization, and develop new applications for its TFX platform technology.

## Funding rounds

- Series B, Oct 7, 2025, $40M — LB Investment, Senvest Management, Sonder Capital
- Series D, Jun 28, 2024, $20M — Sonder Capital

## Investors

- Sonder Capital (https://capitalatlas.ai/funds/sonder-capital) — Series D, Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series B
- Senvest Management — Series B